Clinical trials: Stage IIIB Non Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab work with or without erlotinib hydrochloride in treating non-smokers with advanced non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00976677
- Testing
- erlotinib hydrochloride, paclitaxel, carboplatin
- Where
- 108 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC (Non-small Cell Lung Cancer)
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
his multicenter, open-label, single-arm phase I/II trial will evaluate the safety, tolerability, and preliminary efficacy of oral paclitaxel solution combined with an immune checkpoint inhibitor and concurrent stereotactic body…
- Trial name
- NCT07754812
- Testing
- Oral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT)
- Where
- 5 sites in China
- Volunteers
- 78 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7
Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer
This phase I/II trial studies the best dose and side effects of anetumab ravtansine when given together with atezolizumab and how well they work in treating participants with non-small cell lung cancer that has spread to other…
- Conditions
- Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03455556
- Testing
- Anetumab Ravtansine, Atezolizumab, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer
A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in NSCLC patients at risk of platinum-containing…
- Trial name
- NCT06143735
- Testing
- Efgbemalenograstim alfa
- Where
- 10 sites in China
- Volunteers
- 99 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer
S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00014196
- Testing
- cisplatin, docetaxel, radiation therapy
- Where
- 97 sites in United States
- Volunteers
- 33 people
- Sponsor
- SWOG Cancer Research Network
Non-Small Cell Lung Cancer (NSCLC)
A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer
The purpose of this study is to determine the dose that the vaccine can be given safely to patients when injected directly into the lung tumor, without any serious side effects.
- Trial name
- VTNSCLC (NCT01574222)
- Testing
- autologous dendritic cell adenovirus CCL21 vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- VA Office of Research and Development
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, EGFR Gene Mutation
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
Phase II, single-arm, open-label study that assess clinical feasibility and safety of neoadjuvant almonertinib followed by 3 cycles neoadjuvant adebrelimab plus chemotherapy in EGFR-mutant stage IIA-IIIB NSCLC followed by…
- Trial name
- NEOVADE (NCT06300424)
- Testing
- almonertinib, Carboplatin, Nab paclitaxel
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Guangdong Provincial People's Hospital
Resectable Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer
This phase II trial studies how well bintrafusp alfa before surgery works in treating patients with non-small cell lung cancer for which the patient has not received treatment in the past (untreated) and that can be removed by…
- Conditions
- Resectable Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8
- Trial name
- NCT04560686
- Testing
- Bintrafusp Alfa, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent…
- Trial name
- IPSOS (NCT03191786)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Vinorelbine, Gemcitabine
- Where
- 91 sites in Argentina, Belgium and 22 more
- Volunteers
- 453 people
- Sponsor
- Hoffmann-La Roche
NSCLC (Non-small Cell Lung Cancer), MRD
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
- Trial name
- CTONG 2508 (NCT07120698)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 115 people
- Sponsor
- Guangdong Association of Clinical Trials
Lung Cancer
Palliative 3-Dimensional Conformal Radiation Therapy in Reducing Radiation Side Effects in Patients With Lung Cancer. ICORG 06-34
RATIONALE: 3-dimensional conformal radiation therapy may lessen side effects caused by palliative radiation therapy and improve the quality of life of patients with lung cancer.
- Trial name
- NCT01176487
- Testing
- questionnaire administration, quality-of-life assessment, 3-dimensional conformal radiation therapy
- Where
- 2 sites in Ireland
- Volunteers
- 40 people
- Sponsor
- Cancer Trials Ireland
Non-Small-Cell Lung Cancer
EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
BIM deletion polymorphism might be associated with a poor clinical response to EGFR-TKIs in patients who had NSCLC with EGFR mutations.
- Trial name
- NCT02859077
- Testing
- EGFR-TKI, Chemotherapy（pemetrexed/gemcitabine）, Chemotherapy（carboplatin）
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Breast Cancer, Colorectal Cancer
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor…
- Conditions
- Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00002475
- Testing
- allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Vincent Medical Center - Los Angeles
Lung Cancer
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00103207
- Testing
- cetuximab
- Where
- 157 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eastern Cooperative Oncology Group
Advanced Lung Carcinoma, Extensive Stage Lung Small Cell Carcinoma
Resiliency Among Older Adults Receiving Lung Cancer Treatment
This trial studies how well physical therapy and progressive muscle relaxation works in improving physical performance and mood in older patients with stage IIIA-B or IV lung cancer who are undergoing treatment.
- Conditions
- Advanced Lung Carcinoma, Extensive Stage Lung Small Cell Carcinoma, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- ROAR-LCT (NCT04229381)
- Testing
- Physical Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung, Neoadjuvant Immunotherapy
Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study
This study intends to conduct a prospective, non-interventional study to compare the survival benefits of different surgical resection patterns for patients with non-small cell lung cancer who have achieved partial response (PR)…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoadjuvant Immunotherapy, Surgery
- Trial name
- NCT07373899
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes.
- Conditions
- Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
- Trial name
- PROPHETIC (NCT04056247)
- Testing
- Plasma sample collection
- Where
- 41 sites in United States, Germany and 3 more
- Volunteers
- 10,000 people
- Sponsor
- OncoHost Ltd.
Lung Cancer
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Different people have different biomarkers (chemical "markers" in the blood that may be related to your reaction to study drugs).
- Trial name
- NCT01248247
- Testing
- Erlotinib, AZD6244, MK-2206
- Where
- 2 sites in United States
- Volunteers
- 334 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
This randomized phase II trial is studying carboplatin, paclitaxel, and vorinostat to see how well they work compared with carboplatin, paclitaxel, and a placebo in treating patients with stage III or stage IV non-small cell lung…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00481078
- Testing
- vorinostat, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.